Whitehawk Therapeutics (WHWK) Debt Ratio (2020 - 2021)
Whitehawk Therapeutics (WHWK) reported Debt Ratio of 0.04 for Q4 2021, down 94.99% year-over-year from 0.76 in Q4 2020, and up 11.24% quarter-over-quarter from 0.03 in Q3 2021.
Whitehawk Therapeutics (WHWK) Debt Ratio (2020 - 2021) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 2 years of Debt Ratio data on file, last reported at 0.04 in Q4 2021.
- Debt Ratio for Q4 2021 came in at 0.04, down 94.99% year-over-year; the trailing twelve-month figure through Dec 2021 was 0.04 (down 94.99% YoY), and the FY2021 annual result was 0.04, down 94.99% from the prior year.
- Debt Ratio improved to 0.04 in Q4 2021 per WHWK's latest filing, from 0.03 in the prior quarter.
- Over five years, Debt Ratio peaked at 0.76 in Q4 2020 and troughed at 0.03 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.18 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Whitehawk Therapeutics | 310.18 Mn | 187.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 0.04 |
| Sep 30, 2021 | 0.03 |
| Dec 31, 2020 | 0.76 |